AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00332488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin & Secretagogues
Description: Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
Study NCT00332488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin & Metformin
Description: Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
Study NCT02955706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-L-Carnitine
Description: TID
Study NCT02955706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Acetyl-L-Carnitine
Description: TID
Study NCT04632212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explicit Tax
Description: To impose an explicit tax on food and beverage items that are eligible for red stop-sign food logos (explained in Intervention 2) as less healthy foods. Explicit tax shows pre-tax prices and a label indicating that the price includes a corresponding tax on the less healthy products.~Food and Beverages: we will impose a 20% tax on sales price of the food items
Study NCT04632212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Labels (with the summary of healthiness of shopping baskets & targets)
Description: To provide the green circle 'healthy choice' food label to items with Nutri-Score A and B, the amber circle 'in between healthy and unhealthy choice' food label to items with Nutri-Score C, and the red stop-sign 'less healthy choice' food label to items with Nutri-Score D and E.~In the presence of food labels,~* Video: subjects will watch a video briefly explaining the food labels on the store.~* My Cart Summary: subjects will be provided a live visual indicator of the healthiness of shoppers' current basket with the recommended healthy baskets goals.
Study NCT04632212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ordering
Description: To order food items by Nutri-Score (high to low).
Study NCT04632212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Within-Group Substitution
Description: To provide substitutes within corresponding food categories that are better than the items that subjects chose in terms of Nutri-Score based on the similarities of price, primary ingredients, flavor, and other characteristics.
Study NCT03158935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
Study NCT03158935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Cohort 1: i.v., 25mg/m2 per day for 5 days
Study NCT03158935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Cohort 1 and 2: i.v., 200mg every 3 weeks
Study NCT03158935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TILs)
Description: Cohort 1 and 2: i.v., 1x10\^10 - 1.6x10\^11 cells
Study NCT03158935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Description: Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day
Study NCT01004029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL
Description: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
Study NCT01004029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
Study NCT03384147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinking
Description: Five different types of alcohol given to participants for 4-5 days in a random sequence for 3 weeks
Study NCT03384147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abstaining
Description: Participants are abstaining from all alcoholic beverages for three weeks
Study NCT02236663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Safety Planing App
Description: The control group App will provide women and friends with basic safety planning information and a brief resource list of IPV resources. The resources will be targeted to college students age 18-24 years. The control group App safety plan is not personalized to woman/friend's safety priorities and danger in the relationship.
Study NCT02236663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized App-Based Safety Decision Aid
Description: Setting of priorities for safety: participants will establish priorities by making pairwise comparisons of importance between 5 factors.~Danger Assessment: asks participants to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger and safety planning information and resources based on their level of danger.~Personalized action plan: Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented tailored to their level of danger and priority settings. The participant is given the option to print results and the personalized plan.
Study NCT04018885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 2.5%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
Study NCT04018885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 5%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
Study NCT04018885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 10%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
Study NCT01796223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: The Partners for Change Outcome Management System, administered at the beginning and ending of every therapy session.
Study NCT01796223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT01395849 — intervention group
Intervention type: DRUG
Intervention: Salmeterol and Fluticasone
Study NCT00695136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride
Study NCT00695136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase REM sleep percentage
Study NCT03300609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT03300609 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Given IV
Study NCT03300609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT03300609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV
Study NCT03300609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT03300609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT03300609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT03300609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT03300609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO
Study NCT03300609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03300609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03300609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03300609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01744743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Description: Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
Study NCT01744743 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: levothyroxine
Description: Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
Study NCT04249050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Impact powder
Description: Oral nutritional supplement containing fish oil, arginine and RNA
Study NCT02448498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Study NCT01346462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Centered Transition Intervention
Description: Community Health Workers will act as PaCT Partners for uninsured/Medicaid patients who are being discharged from the Hospital of the University of Pennsylvania and Presbyterian Hospital. PaCT Partners will help patients to overcome the challenges of transition, including arranging primary care provider (PCP) follow-up, filling medication prescriptions and obtaining referrals to community-based social services.
Study NCT02531399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDOCT
Description: Measurement of retinal blood velocities
Study NCT02531399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LDV
Description: Measurement of retinal blood velocities
Study NCT02531399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DVA
Description: Measurement of retinal vessel diameters
Study NCT02531399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSFG
Description: Imaging of retinal blood flow
Study NCT00130910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole 400mg x 3 first dose observed
Study NCT00130910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Albendazole Placebo 400mg x 3 first dose observed
Study NCT00601822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT)
Description: CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.
Study NCT00601822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
Study NCT00008320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceramide
Study NCT02572635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PnuBioVax
Description: Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.
Study NCT02572635 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.
Study NCT02979171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway Classic
Study NCT03440047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuji Flim Processor VP-7000, Light Source BL-7000
Description: Fujifilm's Digital Video Processor VP-7000 and LED Light Source BL-7000 is a class II Endoscopic Video Imaging System under 21 C.F.R. 876.1500. It is the next generation of Fujifilm's VP-4440HD Digital Video Processor with Flexible-spectral Imaging Color Enhancement (FICE) and Light Source (K140149).
Study NCT02311777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin will be given orally during preoperative period
Study NCT02311777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be given on the surgery day before the anesthesia induction
Study NCT02311777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally during preoperative period
Study NCT01979289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized cognitive remediation
Study NCT01979289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computerized cognitive remediation:Control
Study NCT03964181 — intervention group
Intervention type: OTHER
Intervention: Change in school start times
Description: Elementary start times changed from 9:00 a.m. to 8:00 a.m.; middle school start times changed from 8:00 a.m. to 8:50 a.m.; high school start times changed from 7:10 a.m. to 8:20 a.m.
Study NCT01875341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP; Nasal continuous positive airway pressure.
Description: Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
Study NCT01875341 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NCPAP; Nasal continuous positive airway pressure.
Description: Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
Study NCT01875341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group
Description: In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
Study NCT01875341 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group
Description: In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
Study NCT05365087 — intervention group
Intervention type: PROCEDURE
Intervention: Transoral Fundoplication and Sleeve Gastrectomy
Description: Transoral Fundoplication procedure completed prior to Sleeve Gastrectomy
Study NCT05365087 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric Bypass
Description: Laparoscopic Roux-en-Y gastric bypass
Study NCT00384865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg, taken orally, once a day for 6 months
Study NCT00384865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81 mg, taken orally, once a day for 6 months
Study NCT00384865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, taken orally, once a day for 6 months
Study NCT00384865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken orally, once a day for 6 months
Study NCT01093599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quit Line plus MTS
Description: This provides the quit line intervention plus the Mindfulness for Smokers Intervention.
Study NCT01093599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quit Line Only
Description: The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
Study NCT00779064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 10mg BID, Semi-sequential, dose escalation.
Study NCT00779064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 20mg BID, Semi-sequential, dose escalation.
Study NCT02475876 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clindamycin
Description: Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;~* Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose =12 mg/kg;~* Cohort 3; No. Subjects = 5; Age >1-2 years; Dose =12 mg/kg.~* Cohort 4; No. Subjects = 4; Age >2-6 years; Dose =12 mg/kg.~* Cohort 5; No. Subjects = 4; Age >6-12 years; Dose =10 mg/kg.~* Cohort 6; No. Subjects = 4; Age >12-16 years; Dose =10 mg/kg.
Study NCT02475876 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: trimethoprim-sulfamethoxazole
Description: Route of administration is PO for all Cohorts. Dosing interval is every 12 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 6 mg/kg.~* Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose = 6 mg/kg.~* Cohort 3; No. Subjects = 5; Age >1-2 years; Dose = 6 mg/kg.~* Cohort 4; No. Subjects = 4; Age >2-6 years; Dose = 6 mg/kg.~* Cohort 5; No. Subjects = 4; Age >6-12 years; Dose = 6 mg/kg.~* Cohort 6; No. Subjects = 4; Age >12-16 years; Dose = 4 mg/kg.
Study NCT03376698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 mg
Description: oral administration of Colchicine 0.5 mg once daily for 12 weeks
Study NCT03376698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.25 mg
Description: oral administration of Colchicine 0.25 mg once daily for 12 weeks
Study NCT03376698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of Placebo once daily for 12 weeks
Study NCT03592498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadiazine, Silver
Description: Application of silver sulfadiazine ointment, bandage covered with gauze and bandage.
Study NCT03592498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin of Nile tilapia
Description: Application of skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.
Study NCT01969084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Study NCT01969084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01969084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microcirculation testing
Description: The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
Study NCT01969084 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcirculation testing
Description: The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
Study NCT01969084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macrocirculation testing
Description: Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).
Study NCT01969084 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Macrocirculation testing
Description: Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).